ConductScience.org, home

Paper23318436

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.

Shortt J and 2 others. Oncogene, 2013. Cited by 78 papers, by iCite.

Cite this record

ConductScience Library. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Papers, record 23318436. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23318436

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
PubMed
Journal
Oncogene
PubMed
Year
2013
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
78
iCite
Relative citation ratio, by iCite
2.08
iCite
Revised in PubMed
2026-10-10
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shortt JJ
2Hsu AKA K
3Johnstone RWR W

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Immunologic FactorsMajor topic
NeoplasmsMajor topic
ThalidomideMajor topic
Animals
Chromosome Deletion
Chromosomes, Human, Pair 5
Epigenesis, Genetic
Humans
Immunomodulation
Multiple Myeloma
Myelodysplastic Syndromes

Source PubMed

Download CSV of topics

References144

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112173037Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.Oncogene2002https://conductscience.org/library/papers/12173037PubMed
218425106Up on the tightrope: natural killer cell activation and inhibition.Nat Immunol2008https://conductscience.org/library/papers/18425106PubMed
39499327Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.Ann Intern Med1998https://conductscience.org/library/papers/9499327PubMed
419966810A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.Nat Med2010https://conductscience.org/library/papers/19966810PubMed
510579967Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.Gastroenterology1999https://conductscience.org/library/papers/10579967PubMed
616940275Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.J Clin Oncol2006https://conductscience.org/library/papers/16940275PubMed
712036901Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.Blood2002https://conductscience.org/library/papers/12036901PubMed
822246035Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.Blood2012https://conductscience.org/library/papers/22246035PubMed
910229238Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity.Nat Med1999https://conductscience.org/library/papers/10229238PubMed
1020974848IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.J Biol Chem2011https://conductscience.org/library/papers/20974848PubMed
1122241792Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Clin Cancer Res2012https://conductscience.org/library/papers/22241792PubMed
129249925Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo.Teratog Carcinog Mutagen1997https://conductscience.org/library/papers/9249925PubMed
1311529908Deregulated cytokine network and defective Th1 immune response in multiple myeloma.Clin Exp Immunol2001https://conductscience.org/library/papers/11529908PubMed
1422031859IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.Blood2011https://conductscience.org/library/papers/22031859PubMed
1517576924Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.Proc Natl Acad Sci U S A2007https://conductscience.org/library/papers/17576924PubMed
1621232561Functional modulation of AMP-activated protein kinase by cereblon.Biochim Biophys Acta2011https://conductscience.org/library/papers/21232561PubMed
178113151Expression of granule protein mRNAs in acute promyelocytic leukemia.Hematol Pathol1993https://conductscience.org/library/papers/8113151PubMed
189154767Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.N Engl J Med1997https://conductscience.org/library/papers/9154767PubMed
1917234786Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.Cancer Res2007https://conductscience.org/library/papers/17234786PubMed
209988267The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia.Nat Genet1999https://conductscience.org/library/papers/9988267PubMed

See all 144 referencesDownload CSV of references

Cited by56

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.

PMIDTitleJournalYearIn PapersSource
42967027Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study.MedComm (2020)2026https://conductscience.org/library/papers/42967027PubMed
42576759[Preliminary investigation into the mechanisms of thalidomide in inhibiting the malignant transformation of oral leukoplakia].Hua Xi Kou Qiang Yi Xue Za Zhi2026https://conductscience.org/library/papers/42576759PubMed
42470200In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma.Chirality2026https://conductscience.org/library/papers/42470200PubMed
41557108Disulfiram-induced c-FOS influences lipid metabolism and angiogenesis in hepatocellular carcinoma.Sci China Life Sci2026https://conductscience.org/library/papers/41557108PubMed
40322475Drug repurposing: Clinical practices and regulatory pathways.Perspect Clin Res2025https://conductscience.org/library/papers/40322475PubMed
39773053Strengthening Effect of Thalidomide Combined with an Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy.Curr Pharm Biotechnol2025https://conductscience.org/library/papers/39773053PubMed
38993289NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.Bladder Cancer2023https://conductscience.org/library/papers/38993289PubMed
38817675(S)-3-aminopiperidine-2,6-dione is a biosynthetic intermediate of microbial blue pigment indigoidine.mLife2022https://conductscience.org/library/papers/38817675PubMed
38646175Inhibitors to degraders: Changing paradigm in drug discovery.iScience2024https://conductscience.org/library/papers/38646175PubMed
37111560Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy.Pharmaceutics2023https://conductscience.org/library/papers/37111560PubMed
36289711Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury.Biomedicines2022https://conductscience.org/library/papers/36289711PubMed
36268122Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.ACS Pharmacol Transl Sci2022https://conductscience.org/library/papers/36268122PubMed
35770527The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.Haematologica2023https://conductscience.org/library/papers/35770527PubMed
35247913AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma.Clin Cancer Res2022https://conductscience.org/library/papers/35247913PubMed
34834536Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.J Pers Med2021https://conductscience.org/library/papers/34834536PubMed
34085173Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Macrophage Polarization by Targeting the Transcription Factor IRF5.Dig Dis Sci2021https://conductscience.org/library/papers/34085173PubMed
33907692TNFR2: Role in Cancer Immunology and Immunotherapy.Immunotargets Ther2021https://conductscience.org/library/papers/33907692PubMed
33860215
N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge.
ACS Pharmacol Transl Sci2021https://conductscience.org/library/papers/33860215PubMed
33195898Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine.ACS Omega2020https://conductscience.org/library/papers/33195898PubMed
32906688Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma.Cancers (Basel)2020https://conductscience.org/library/papers/32906688PubMed

See all 56 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23318436

GET https://conductscience.org/api/papers/v1/23318436/references?page=2